All In Biotech

Drug Trial Radar · NCT07289776

A First-in-human Trial of GRT7041 in Healthy Participants

A Randomized, Single-center, Double-blind, Placebo-controlled, First-in-human Trial With Single and Multiple Ascending Doses to Determine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GRT7041 in Healthy Participants.

Last checked: Nov 20, 2026Latest source record: Feb 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jan 14, 2026

Primary completion

Aug 24, 2026

Study completion Aug 28, 2026

Sponsor

Lead sponsor
Grünenthal GmbHIndustry
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this trial is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GRT7041 in healthy male and female (Women of non-childbearing potential) participants. The trial duration will be up to approximately 6 weeks for participants in Part 1 (Single ascending dose \[SAD\]), except for participants taking part in the food effect cohort SAD3 where the trial duration will be up to approximately 8 weeks. The trial duration will be up to approximately 7 weeks in Part 2 (Multiple ascending dose \[MAD\]), and the Treatment Period will be up to 14 days (for Part 2). The trial will include a Screening Visit, an in-house stay period and Follow-up (FU) Visit/End-of-Trial (EoT) Visit.

Conditions

  • Treatment of Pain

Interventions

  • GRT7041 SADDrug

    Single ascending doses

  • PlaceboDrug

    Placebo to match GRT7041 dose strength

  • MidazolamDrug

    Solution

  • GRT7041 MADDrug

    Multiple ascending doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse EventsTime frame: Through study completion, an average of 8 Weeks
  2. Number of participants with Serious Adverse EventsTime frame: Through study completion, an average of 8 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research (NZCR)

    Christchurch, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.